SCYNEXIS, Inc. (SCYX) News & Overview - Discounting Cash Flows
SCYX
SCYNEXIS, Inc.
SCYX (NASDAQ)

SCYX's Business Model

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Sector & Industry Healthcare / Drug Manufacturers - Specialty & Generic
Website https://www.scynexis.com
CEO (Chief Executive Officer) David Gonzalez Angulo
Number of Employees
IPO date May 2, 2014

SCYX Latest News

Contact
CountryUS
Address1 Evertrust Plaza
CityJersey City
StateNJ
Phone201 884 5485
Zip Code07302-6548
Other Identifiers
CIK0001178253
ISINUS8112922005
CUSIP811292200
Open0.708
Previous Close0.7078
Volume208.4 Thou.
Average Volume138.2 Thou.
Day’s Range0.7079 – 0.738
52 Week Range0.66-2.29
MA (50)0.84928
MA (200)1.09845
Market Cap27.72 Mil.
Shares Out.39.02 Mil.
Earnings DateAug 06, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for SCYX

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us